Medical Cannabis Use in France: An Observational Safety Study Based on the RECANN Registry and the Pharmacovigilance/Addictovigilance System From 2021 to 2024

Documenti analoghi

• Cannabinoids and Adverse Convulsive Effects: A Pharmacovigilance and Addictovigilance Analysis of Cases Reported in France
  di: Marie‐Laure Laroche, et al.
  Pubblicazione: (2025)
• Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network
  di: Pauline Gandolfo, et al.
  Pubblicazione: (2024)
• JAK Inhibitors and Memory Impairment: Disproportionality Analyses in the WHO Global Pharmacovigilance Database, VigiBase
  di: Marilou Duboëlle, et al.
  Pubblicazione: (2026)
• Relapse and New‐Onset of Autoimmune or Inflammatory Diseases Following Vaccination With SPIKEVAX: Pharmacovigilance Overview From the French Spontaneous Reported System
  di: Lucie Vettoretti, et al.
  Pubblicazione: (2025)
• Sex and Age Differences in Suspected Bleeding Reporting With Acetyl Salicylic Acid: A Descriptive Study in the Global Pharmacovigilance Database, Vigibase
  di: Jean‐Louis Montastruc, et al.
  Pubblicazione: (2025)